Now showing items 1-20 of 43

    • Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling. 

      Baker, LCJ; Boult, JKR; Thomas, M; Koehler, A; Nayak, T; Tessier, J; Ooi, C-H; Birzele, F; Belousov, A; Zajac, M; Horn, C; LeFave, C; Robinson, SP (2016-09)
      BACKGROUND:To assess antivascular effects, and evaluate clinically translatable magnetic resonance imaging (MRI) biomarkers of tumour response in vivo, following treatment with vanucizumab, a bispecific human antibody ...
    • The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. 

      Guan, J; Tucker, ER; Wan, H; Chand, D; Danielson, LS; Ruuth, K; El Wakil, A; Witek, B; Jamin, Y; Umapathy, G; Robinson, SP; Johnson, TW; Smeal, T; Martinsson, T; Chesler, L; Palmer, RH; Hallberg, B (2016-09)
      The first-in-class inhibitor of ALK, c-MET and ROS1, crizotinib (Xalkori), has shown remarkable clinical efficacy in treatment of ALK-positive non-small cell lung cancer. However, in neuroblastoma, activating mutations in ...
    • Assessment of the direct effects of DDAH I on tumour angiogenesis in vivo. 

      Papaevangelou, E; Boult, JKR; Whitley, GS; Robinson, SP; Howe, FA (2018-11)
      Nitric oxide (NO) has been strongly implicated in glioma progression and angiogenesis. The endogenous inhibitors of NO synthesis, asymmetric dimethylarginine (ADMA) and N-monomethyl-L-arginine (L-NMMA), are metabolized by ...
    • Characterisation of fibrosis in chemically-induced rat mammary carcinomas using multi-modal endogenous contrast MRI on a 1.5T clinical platform. 

      Jerome, NP; Boult, JKR; Orton, MR; d'Arcy, JA; Nerurkar, A; Leach, MO; Koh, D-M; Collins, DJ; Robinson, SP (2018-04)
      OBJECTIVES:To determine the ability of multi-parametric, endogenous contrast MRI to detect and quantify fibrosis in a chemically-induced rat model of mammary carcinoma. METHODS:Female Sprague-Dawley rats (n=18) were ...
    • Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease. 

      Hill, RM; Kuijper, S; Lindsey, JC; Petrie, K; Schwalbe, EC; Barker, K; Boult, JKR; Williamson, D; Ahmad, Z; Hallsworth, A; Ryan, SL; Poon, E; Robinson, SP; Ruddle, R; Raynaud, FI; Howell, L; Kwok, C; Joshi, A; Nicholson, SL; Crosier, S; Ellison, DW; Wharton, SB; Robson, K; Michalski, A; Hargrave, D; Jacques, TS; Pizer, B; Bailey, S; Swartling, FJ; Weiss, WA; Chesler, L; Clifford, SC (2015-01)
      We undertook a comprehensive clinical and biological investigation of serial medulloblastoma biopsies obtained at diagnosis and relapse. Combined MYC family amplifications and P53 pathway defects commonly emerged at relapse, ...
    • Correlation of Ultrasound Shear Wave Elastography with Pathological Analysis in a Xenografic Tumour Model. 

      Elyas, E; Papaevangelou, E; Alles, EJ; Erler, JT; Cox, TR; Robinson, SP; Bamber, JC (2017-03-13)
      The objective of this study was to evaluate the potential value of ultrasound (US) shear wave elastography (SWE) in assessing the relative change in elastic modulus in colorectal adenocarcinoma xenograft models in vivo and ...
    • Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma. 

      Dolman, MEM; Poon, E; Ebus, ME; den Hartog, IJM; van Noesel, CJM; Jamin, Y; Hallsworth, A; Robinson, SP; Petrie, K; Sparidans, RW; Kok, RJ; Versteeg, R; Caron, HN; Chesler, L; Molenaar, JJ (2015-11)
      PURPOSE:MYCN-dependent neuroblastomas have low cure rates with current multimodal treatment regimens and novel therapeutic drugs are therefore urgently needed. In previous preclinical studies, we have shown that targeted ...
    • Detecting human melanoma cell re-differentiation following BRAF or heat shock protein 90 inhibition using photoacoustic and magnetic resonance imaging. 

      Shah, A; Delgado-Goni, T; Casals Galobart, T; Wantuch, S; Jamin, Y; Leach, MO; Robinson, SP; Bamber, J; Beloueche-Babari, M (2017-08-15)
      Targeted therapies specific to the BRAF-MEK-ERK signaling pathway have shown great promise in the treatment of malignant melanoma in the last few years, with these drugs now commonly used in clinic. Melanoma cells treated ...
    • Detection of the prodrug-activating enzyme carboxypeptidase G2 activity with chemical exchange saturation transfer magnetic resonance. 

      Jamin, Y; Eykyn, TR; Poon, E; Springer, CJ; Robinson, SP (2014-04)
      PURPOSE:The purpose of this study is to evaluate if the differential exchange rates with bulk water between amine and amide protons can be exploited using chemical exchange saturation transfer magnetic resonance (CEST-MR) ...
    • Dichloroacetate induces autophagy in colorectal cancer cells and tumours. 

      Lin, G; Hill, DK; Andrejeva, G; Boult, JKR; Troy, H; Fong, A-CLFWT; Orton, MR; Panek, R; Parkes, HG; Jafar, M; Koh, D-M; Robinson, SP; Judson, IR; Griffiths, JR; Leach, MO; Eykyn, TR; Chung, Y-L (2014-07)
      Dichloroacetate (DCA) has been found to have antitumour properties.We investigated the cellular and metabolic responses to DCA treatment and recovery in human colorectal (HT29, HCT116 WT and HCT116 Bax-ko), prostate carcinoma ...
    • Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy. 

      Papaevangelou, E; Almeida, GS; Jamin, Y; Robinson, SP; deSouza, NM (2015-04-16)
      BACKGROUND:Non-invasive serial imaging is desirable to detect processes such as necrotic and apoptotic cell death in cancer patients undergoing treatment. This study investigated the use of diffusion-weighted (DW-) magnetic ...
    • Evaluating Imaging Biomarkers of Acquired Resistance to Targeted EGFR Therapy in Xenograft Models of Human Head and Neck Squamous Cell Carcinoma. 

      Baker, LCJ; Sikka, A; Price, JM; Boult, JKR; Lepicard, EY; Box, G; Jamin, Y; Spinks, TJ; Kramer-Marek, G; Leach, MO; Eccles, SA; Box, C; Robinson, SP (2018-01)
      Background: Overexpression of EGFR is a negative prognostic factor in head and neck squamous cell carcinoma (HNSCC). Patients with HNSCC who respond to EGFR-targeted tyrosine kinase inhibitors (TKIs) eventually develop ...
    • Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI. 

      Boult, JKR; Box, G; Vinci, M; Perryman, L; Eccles, SA; Jones, C; Robinson, SP (2017-09)
      Vascular endothelial growth factor A (VEGF-A) is considered one of the most important factors in tumor angiogenesis, and consequently, a number of therapeutics have been developed to inhibit VEGF signaling. Therapeutic ...
    • Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues. 

      Khan, AA; Paget, JT; McLaughlin, M; Kyula, JN; Wilkinson, MJ; Pencavel, T; Mansfield, D; Roulstone, V; Seth, R; Halle, M; Somaiah, N; Boult, JKR; Robinson, SP; Pandha, HS; Vile, RG; Melcher, AA; Harris, PA; Harrington, KJ (2018-01)
      Improvements in cancer survival mean that long-term toxicities, which contribute to the morbidity of cancer survivorship, are being increasingly recognized. Late adverse effects (LAEs) in normal tissues after radiotherapy ...
    • Imaging biomarker roadmap for cancer studies. 

      O'Connor, JPB; Aboagye, EO; Adams, JE; Aerts, HJWL; Barrington, SF; Beer, AJ; Boellaard, R; Bohndiek, SE; Brady, M; Brown, G; Buckley, DL; Chenevert, TL; Clarke, LP; Collette, S; Cook, GJ; deSouza, NM; Dickson, JC; Dive, C; Evelhoch, JL; Faivre-Finn, C; Gallagher, FA; Gilbert, FJ; Gillies, RJ; Goh, V; Griffiths, JR; Groves, AM; Halligan, S; Harris, AL; Hawkes, DJ; Hoekstra, OS; Huang, EP; Hutton, BF; Jackson, EF; Jayson, GC; Jones, A; Koh, D-M; Lacombe, D; Lambin, P; Lassau, N; Leach, MO; Lee, T-Y; Leen, EL; Lewis, JS; Liu, Y; Lythgoe, MF; Manoharan, P; Maxwell, RJ; Miles, KA; Morgan, B; Morris, S; Ng, T; Padhani, AR; Parker, GJM; Partridge, M; Pathak, AP; Peet, AC; Punwani, S; Reynolds, AR; Robinson, SP; Shankar, LK; Sharma, RA; Soloviev, D; Stroobants, S; Sullivan, DC; Taylor, SA; Tofts, PS; Tozer, GM; van Herk, M; Walker-Samuel, S; Wason, J; Williams, KJ; Workman, P; Yankeelov, TE; Brindle, KM; McShane, LM; Jackson, A; Waterton, JC (2017-03)
      Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET ...
    • Imaging tumour hypoxia with oxygen-enhanced MRI and BOLD MRI. 

      O'Connor, JPB; Robinson, SP; Waterton, JC (2019-03)
      Hypoxia is known to be a poor prognostic indicator for nearly all solid tumours and also is predictive of treatment failure for radiotherapy, chemotherapy, surgery and targeted therapies. Imaging has potential to identify, ...
    • Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. 

      Tucker, ER; Tall, JR; Danielson, LS; Gowan, S; Jamin, Y; Robinson, SP; Banerji, U; Chesler, L (2017-08)
      Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more ...
    • In Vivo Modeling of Chemoresistant Neuroblastoma Provides New Insights into Chemorefractory Disease and Metastasis. 

      Yogev, O; Almeida, GS; Barker, KT; George, SL; Kwok, C; Campbell, J; Zarowiecki, M; Kleftogiannis, D; Smith, LM; Hallsworth, A; Berry, P; Möcklinghoff, T; Webber, HT; Danielson, LS; Buttery, B; Calton, EA; da Costa, BM; Poon, E; Jamin, Y; Lise, S; Veal, GJ; Sebire, N; Robinson, SP; Anderson, J; Chesler, L (2019-10)
      Neuroblastoma is a pediatric cancer that is frequently metastatic and resistant to conventional treatment. In part, a lack of natively metastatic, chemoresistant in vivo models has limited our insight into the development ...
    • Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. 

      Clarke, M; Mackay, A; Ismer, B; Pickles, JC; Tatevossian, RG; Newman, S; Bale, TA; Stoler, I; Izquierdo, E; Temelso, S; Carvalho, DM; Molinari, V; Burford, A; Howell, L; Virasami, A; Fairchild, AR; Avery, A; Chalker, J; Kristiansen, M; Haupfear, K; Dalton, JD; Orisme, W; Wen, J; Hubank, M; Kurian, KM; Rowe, C; Maybury, M; Crosier, S; Knipstein, J; Schüller, U; Kordes, U; Kram, DE; Snuderl, M; Bridges, L; Martin, AJ; Doey, LJ; Al-Sarraj, S; Chandler, C; Zebian, B; Cairns, C; Natrajan, R; Boult, JKR; Robinson, SP; Sill, M; Dunkel, IJ; Gilheeney, SW; Rosenblum, MK; Hughes, D; Proszek, PZ; Macdonald, TJ; Preusser, M; Haberler, C; Slavc, I; Packer, R; Ng, H-K; Caspi, S; Popović, M; Faganel Kotnik, B; Wood, MD; Baird, L; Davare, MA; Solomon, DA; Olsen, TK; Brandal, P; Farrell, M; Cryan, JB; Capra, M; Karremann, M; Schittenhelm, J; Schuhmann, MU; Ebinger, M; Dinjens, WNM; Kerl, K; Hettmer, S; Pietsch, T; Andreiuolo, F; Driever, PH; Korshunov, A; Hiddingh, L; Worst, BC; Sturm, D; Zuckermann, M; Witt, O; Bloom, T; Mitchell, C; Miele, E; Colafati, GS; Diomedi-Camassei, F; Bailey, S; Moore, AS; Hassall, TEG; Lowis, SP; Tsoli, M; Cowley, MJ; Ziegler, DS; Karajannis, MA; Aquilina, K; Hargrave, DR; Carceller, F; Marshall, LV; von Deimling, A; Kramm, CM; Pfister, SM; Sahm, F; Baker, SJ; Mastronuzzi, A; Carai, A; Vinci, M; Capper, D; Popov, S; Ellison, DW; Jacques, TS; Jones, DTW; Jones, C (2020-07)
      Infant high-grade gliomas appear clinically distinct from their counterparts in older children, indicating that histopathologic grading may not accurately reflect the biology of these tumors. We have collected 241 cases ...
    • Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. 

      Vaughan, L; Clarke, PA; Barker, K; Chanthery, Y; Gustafson, CW; Tucker, E; Renshaw, J; Raynaud, F; Li, X; Burke, R; Jamin, Y; Robinson, SP; Pearson, A; Maira, M; Weiss, WA; Workman, P; Chesler, L (2016-09)
      MYC oncoproteins deliver a potent oncogenic stimulus in several human cancers, making them major targets for drug development, but efforts to deliver clinically practical therapeutics have not yet been realized. In childhood ...